

## Curriculum Vitae

**Dr. Ralf Reilmann**

**Founding Director**

Professional address: George-Huntington-Institute  
Technology-Park Muenster – Deilmann Building  
Johann-Krane Weg 27  
48149 Muenster  
Germany

Phone (office): +49-251-788-788-11  
Phone (coordinator): +49-251-788-788-0  
Fax: +49-251-788-788-88  
Mobile: +49-151-106-499-44  
Email: [ralf.reilmann@ghi-muenster.de](mailto:ralf.reilmann@ghi-muenster.de)  
Web : [www.ghi-muenster.de](http://www.ghi-muenster.de)

Academic affiliations: Department of Radiology, University of Muenster,  
Dept. of Neurodegenerative Diseases & Hertie-Institute  
for Clinical Brain Research, University of Tuebingen,  
Germany



### PERSONAL STATEMENT

My main interest is to contribute to the development of disease modifying or novel symptomatic therapies for neurodegenerative diseases. On this path, I chose to focus my work on Huntington's disease (HD) as a genetically defined model of a neurodegenerative disease with relevant patient populations and availability of well-defined preclinical models. As founder of the George-Huntington-Institute and formerly chair of the Huntington Unit at the Department of Neurology, University of Muenster, Germany, I established one of the largest cohorts of symptomatic and premanifest HD gene carriers globally (currently ~ 500 participants in ENROLL-HD). I now establish a second cohort of HD patients at the Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research, University of Tuebingen, Germany and hold a research position for Imaging in HD at the Dept. of Radiology of the University of Muenster. I serve as elected member of the Executive Committees of the European Huntington's Disease Network (EHDN – [www.euro-hd.net](http://www.euro-hd.net)) and the Huntington Study Group ([www.huntingtonstudygroup.org](http://www.huntingtonstudygroup.org)) and as Global Coordinating Principle Investigator of several randomized multicenter clinical trials in HD. As Chair of the "Neuroprotective Therapy Working Group" and the "Motor Phenotype Working Group" of EHDN I coordinate several biomarker, preclinical and clinical initiatives. I also established the EHDN UHDRS-TMS (Unified Huntington's Disease Rating Scale - Total Motor Score) online certification for improved standardization of motor ratings, which is now required for all observational and clinical trials in HD. My main line of research focuses on the development of objective and quantitative motor ("Q-Motor") outcome measures for clinical trials, e.g., in the setting of research studies such as TRACK-HD ([www.track-hd.net](http://www.track-hd.net)), REPAIR-HD ([www.repair-hd.eu](http://www.repair-hd.eu)) and several clinical trials (e.g. PRIDE-HD, LEGATO-HD, SIGNAL, AMARYLLIS, AFQ056). Q-Motor systems are established for collaborative work in > 100 centers of excellence for Movement Disorders and other neurodegenerative diseases worldwide and meanwhile serve as standardized outcome measures in several phase I-III clinical trials in HD and Parkinson's disease. Additional studies explore the applicability of Q-Motor endpoints in, e.g., Multiple Sclerosis, Myasthenia, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Dystonia, and Prion diseases. A second line of research aims to develop and phenotype large animal models of HD for translational assessments of novel therapeutic approaches for HD using imaging, behavioural and molecular measures. I trained at the University of Muenster (Germany) and at Columbia University (New York) and studied in Muenster, Paris, London, and New York. My work was funded by, e.g., the High-Q-Foundation/CHDI Foundation ([www.chdifoundation.org](http://www.chdifoundation.org)), the German Research Foundation ([www.dfg.de](http://www.dfg.de)), the European Union (EUFP7 program), and the German National Scholarship Foundation ([www.studienstiftung.de](http://www.studienstiftung.de)).

## PROFESSIONAL POSITIONS

2014 – ongoing	HD Research Group Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tübingen Chairman: Thomas Gasser, MD, Professor of Neurology
2014 – ongoing	HD imaging biomarker research Dept. of Radiology, University of Muenster, Muenster, Germany Chairman: Walter Heindel, MD, Professor of Neurology
2013 – ongoing	Founding Director George-Huntington-Institute Muenster, Germany
2007 – 2015	Board Certified Neurologist / Founder and Supervisor of the Huntington Clinic Dept. of Neurology, University of Muenster, Muenster, Germany Chairman: E. Bernd Ringelstein, MD, Professor of Neurology
2006 – 2007	Medical Doctor / Clinical appointment Dept. of Psychiatry, University of Muenster, Muenster, Germany Chairman: V. Arolt, MD, Professor of Psychiatry
2001 – 2005	Medical Doctor / Resident & Fellow, Clinical appointment Dept. of Neurology, University of Muenster, Muenster, Germany Chairman: E. Bernd Ringelstein, MD, Professor of Neurology
1997 – 2001	Postdoctoral Research Fellow (Grant of DFG and NSF) Dept. of Biobehav. Sciences & Neurology, Columbia University, New York, NY, USA Chairman: Andrew M. Gordon, Ph.D., Professor for Physiology
1996 – 1997	Junior Resident („Arzt im Praktikum“) / Clinical appointment Dept. of Neurology, University of Muenster, Muenster, Germany Chairman: E. Bernd Ringelstein, MD, Professor of Neurology
1995 – 1997	Dissertation („doctor medicinae“ / Grade: “Summa cum laude” (with honours)

## MEDICAL EXAMS

1995	German Medical State Exam, i.e. Medical Degree, University of Muenster, Germany Grade: very good (with honours)
1995	US Medical Degree, United States Medical Licensing Exam USMLE step 1 (basic science) and step 2 (clinical science)

## UNIVERSITY EDUCATION

1995	University of London, London, Great Britain / Clinical Neurology Internship National Hospital for Neurology and Neurosurgery / C. D. Marsden, MD FRCP
1994	Cornell University, New York, NY, USA / Oncology Internship Memorial Sloan Kettering Cancer Center / Alan Houghton, MD
1994	Université de Paris Pierre et Marie Curie, Paris, France / Surgery Internship Hôpital St. Antoine, Département de Chirurgie Viscérale / Rolland Parc, MD
1993	German National Cancer Institute (DKFZ), Heidelberg, Germany / Research Internship Laboratory of Molecular Genetics / A. Poustka, PhD
1992	Clinical electives in USA with scholarship of “Studienstiftung des Deutschen Volkes”: Cornell University Medical School, New York, NY Rockefeller University, New York, NY East Carolina University, Greenville, NC
1988 – 1995	Grant of the “Studienstiftung des Deutschen Volkes” (German National Scholarship Foundation)
1988 – 1995	University of Muenster Medical School, Muenster, Germany Preclinical and Clinical Studies of Medicine

## ARMY SERVICE

1987 – 1988	Medical Service of the German Army
-------------	------------------------------------

## SCHOOL EDUCATION

1984	Roosevelt High School, Fresno, CA, USA / exchange student (scholarship of the City of Muenster)
1978 – 1987	Paulinum High School, Muenster, Germany, Graduation (Abitur): very good (1,2)

## MEMBERSHIP IN PROFESSIONAL SOCIETIES

2003 – ongoing	European Huntington's Disease Network (EHDN)
2000 – ongoing	Movement Disorders Society (MDS)
2000 – ongoing	Deutsche Gesellschaft für Neurologie (Germany Neurological Society) (DGN)
1998 – ongoing	Society for Neuroscience (SFN)
1997 – ongoing	American Academy of Neurology (AAN)

## EDITORIAL BOARD MEMBERSHIPS

2013 – ongoing	Academic Editor – PLOS-ONE
2011 – ongoing	Associate Editor - Journal of Huntington's Disease
2011 – 2015	Member of the Editorial Board of the Movement Disorders Journal
2010 – ongoing	Member of the Editorial Board of PLoS Currents Huntington's Disease
2010 – ongoing	Member of the Editorial Board of Frontiers in Movement Disorders

## PROFESSIONAL / HONORARY POSITIONS

2015 – ongoing	Co-Chair of the Movement Disorders Society Task Force on the Redefinition of diagnostic criteria for Huntington's disease ( <a href="http://www.movementdisorders.org">www.movementdisorders.org</a> )
2014 – ongoing	Member of the Movement Disorders Society Technology Task Force ( <a href="http://www.movementdisorders.org">www.movementdisorders.org</a> )
2014 – ongoing	Member of the Executive Committee of the Huntington Study Group ( <a href="http://www.huntingtonstudygroup.org">www.huntingtonstudygroup.org</a> )
2012 – ongoing	Elected Member of the Executive Committee of the European Huntington's Disease Network ( <a href="http://www.euro-hd.net">www.euro-hd.net</a> )
2012 – ongoing	Elected Member of the Scientific Review Committee of the ENROLL-HD observational study ( <a href="http://www.enroll-hd.net">www.enroll-hd.net</a> )
2012 – 2015	Member of the Clinical Trials Task Force, European Huntington's Disease Network ( <a href="http://www.euro-hd.net">www.euro-hd.net</a> )
2012 – ongoing	Member of the Editorial Board of the patient information pamphlet "HD-Insights".
2009 – 2012	Elected Member of the Scientific and Bioethics Advisory Committee of the European Huntington's Disease Network ( <a href="http://www.euro-hd.net">www.euro-hd.net</a> )
2009 – ongoing	Member of the Scientific Advisory Board of the Jacques and Gloria Gossweiler Foundation, Switzerland
2008 – ongoing	Scientific Consultant and Writer, "Huntington Kurier", Newsletter of the German Huntington's Disease Society (Deutsche Huntington Hilfe, e.V.) ( <a href="http://www.dhh-ev.net">www.dhh-ev.net</a> )
2008 – 2015	Co-Chair, Motor Committee, PREDICT-HD Multicenter Study
2007 – ongoing	Lead Facilitator, Neuroprotective Working Group, European Huntington's Disease Network ( <a href="http://www.euro-hd.net">www.euro-hd.net</a> )
2006 – ongoing	Member of clinical guideline expert group on Huntington's Disease of the German Academy for Neurology ( <a href="http://www.dgn.org">www.dgn.org</a> )
2005 – ongoing	Lead Facilitator, Motor Phenotype Assessment Working Group, European Huntington's Disease Network ( <a href="http://www.euro-hd.net">www.euro-hd.net</a> )
2004 – ongoing	German National Scholarship Foundation (Studienstiftung des Deutschen Volkes) - Member of admission's committee ( <a href="http://www.studienstiftung.de">www.studienstiftung.de</a> )
2002 – ongoing	Member of the Scientific Advisory Board / German Huntington's Disease Society (Deutsche Huntington Hilfe, e.V.) ( <a href="http://www.dhh-ev.net">www.dhh-ev.net</a> )
1998 – 1999	Member of the Board of Trustees, International House New York Chairman: Paul A. Volker / Honorary Chairman: David Rockefeller & Henry Kissinger ( <a href="http://www.ihouse-nyc.org">www.ihouse-nyc.org</a> )

**CLINICAL TRIAL / TRANSLATIONAL MEDICINE EXPERIENCE****GLOBAL COORDINATING PRINCIPLE INVESTIGATOR**

2016 – ongoing	Global Coordinating Principle Investigator – Phase I clinical trial with AAV5-miHTT (uniQure/ EUDRACT pending)
2013 – ongoing	Global Coordinating Principle Investigator – Phase I clinical trial with BN82451B (Ipsen Pharma/ EUDRACT 2013-002899-41)
2013 – ongoing	Global Coordinating Principle Investigator – LEGATO-HD – Phase II clinical trial with Laquinimod (TEVA Pharmaceuticals/ EUDRACT 2014-000418M5)
2013 – ongoing	Global Coordinating Principle Investigator EU – PRIDE-HD – Phase IIb clinical trial Pridopidine (TEVA Pharmaceuticals/ EUDRACT 2013-001888-23)
2011 – 2012	Global Coordinating Principle Investigator – Phase IIa clinical trial Selisistat (SEN-014) (Siena Biotech / EUDRACT 2011-001131-23)
2011 – 2012	Global Coordinating Principle Investigator – Phase IIa clinical trial AFQ-056 (Novartis / EUDRACT 2009-011743-39)

**LOCAL SITE PRINCIPLE INVESTIGATOR**

2014 – ongoing	Site Principle Investigator – AMARYLLIS – Phase II clinical trial with PF-02545920 (Pfizer/ EUDRACT 2014-001291-56)
2014 – ongoing	Site Principle Investigator – ENROLL-HD observational study (CHDI-Foundation)
2014 – ongoing	Site Principle Investigator – LEGATO-HD – Phase II clinical trial with Laquinimod (TEVA Pharmaceuticals/ EUDRACT 2014-000418M5)
2014 – ongoing	Site Principle Investigator – PRIDE-HD – Phase IIb clinical trial with Pridopidine (TEVA Pharmaceuticals/ EUDRACT 2013-001888-23)
2011 – 2012	Site Principle Investigator – Phase IIa clinical trial with Selisistat (SEN-014) (Siena Biotech / EUDRACT 2011-001131-23)
2009 – 2012	Site Principle Investigator – Phase IIa clinical trial with AFQ-056 (Novartis / EUDRACT 2009-011743-39)
2009 – 2011	Site Principle Investigator – HORIZON – Phase III clinical trial with Dimebon (Medivation/Pfizer / EUDRACT 2009-011800-44)
2008 – 2009	Site Principle Investigator – MERMAI-HD – Phase III clinical trial with Pridopidine (ACR-16) Neuroserach / EUDRACT 2007-004988-22)
2005 – 2007	Site Principle Investigator – Phase III clinical trial with LAX-101 (Amarin / EUDRACT 2005-002088-98)
2004 – 2014	Site Principle Investigator – REGISTRY observational Study (European Huntington's disease Network / CHDI-Foundation)

**STEERING COMMITTEE MEMBERSHIPS**

2013 – ongoing	Member of the Steering Committee – A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease (Sponsor: TEVA Pharmaceuticals, Israel); Countries: Canada, Czech Republic, France, Germany, Netherlands, Portugal, Spain, United Kingdom, USA.
2013 – ongoing	Member of the Steering Committee – A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington's Disease (Sponsor: TEVA Pharmaceuticals, Israel); Countries: Australia, Austria, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Portugal, Russia, United Kingdom, USA.
2011 – ongoing	Member of the Steering Committee – A randomized, double-blind, placebo-controlled study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to

- mid-stage Huntington disease, Phase IIa (Sponsor: Prana Pharmaceuticals, Australia); Countries: Australia, Canada, USA.
- 2011 – ongoing Member of the Steering Committee – Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196 (EUDRACT 2011-001131-23), Phase IIa (Sponsor: Siena Biotech, Italy); Countries: Germany, Great Britain, Italy.
- 2011 – ongoing Member of the Steering Committee – TRACK-ON-HD biomarker study, Observational Biomarker Study (Sponsor: CHDI Foundation, USA); Countries: Great Britain, France, Netherlands, Canada.
- 2009 – 2015 Member of the Steering Committee – A multi-center, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea (EUDRACT 2009-011743-39), Phase IIa (Sponsor: Novartis, Switzerland); Countries: Germany, Great Britain, USA.
- 2008 – ongoing Member of the Steering Committee – TRACK-HD biomarker study, Observational Biomarker Study (Sponsor: CHDI Foundation, USA); Countries: Great Britain, France, Netherlands, Canada.

### CLINICAL TRIAL TRAINING

- 2013 University of Muenster, Clinical Trials Coordination Center, Muenster, Germany  
Teaching course for principle investigators of investigator initiated clinical trials.
- 2009 NINDS Clinical Trials Methods in Neurology Course, Vail Colorado, USA, with sponsorship of CHDI Foundation (<http://www.neurologytrials.org>) (Mentors: Ira Shoulson, MD, Mike Poole, MD)

### PUBLICATIONS

(peer reviewed)

- Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, **Reilmann R**, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S; Movement Disorders Society Task Force on Technology. Technology in Parkinson's disease: Challenges and opportunities. *Mov Disord*. 2016 Apr 29. doi: 10.1002/mds.26642. [Epub ahead of print] Review. PubMed PMID: 27125836
- Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, **Reilmann R**, Borowsky B, Stout J, Craufurd D, Tabrizi SJ. Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. *PLoS Curr*. 2016 Jan 11;8. pii: ecurrents.hd.8060298fac1801b01ccea6acc00f97cb
- Hoffmann S, Siedler J, Brandt AU, Piper SK, Kohler S, Sass C, Paul F, **Reilmann R**, Meisel A. Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. *BMC Neurol*. 2015 Dec 23;15:265
- Schramke S, Schuldenzucker V, Schubert R, Frank F, Wirsig M, Ott S, Motlik J, Fels M, Kemper N, Hölzner E, **Reilmann R**. Behavioral phenotyping of minipigs transgenic for the Huntington gene. *J Neurosci Methods*. 2016, 30:265:34-45
- Schubert R, Frank F, Nagelmann N, Liebsch L, Schuldenzucker V, Schramke S, Wirsig M, Johnson H, Kim EY, Ott S, Hölzner E, Demokritov SO, Motlik J, Faber C, **Reilmann R**. Neuroimaging of a minipig model of Huntington's disease: Feasibility of volumetric, diffusion-weighted and spectroscopic assessments. *J Neurosci Methods*. 2016, 265:46-55
- Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, Roos RA, Leavitt BR, Papoutsis M, Landwehrmeyer GB, **Reilmann R**, Borowsky B, Johnson H, Mills JA, Owen G, Stout J, Scahill RI, Long JD, Rees G, Tabrizi SJ; Track-On investigators. Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. *EBioMedicine*. 2015, 2:1420-9
- Johnson EB, Rees EM, Labuschagne I, Durr A, Leavitt BR, Roos RA, **Reilmann R**, Johnson H, Hobbs NZ, Langbehn DR, Stout JC, Tabrizi SJ, Scahill RI; TRACK-HD investigators. The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. *Neuropsychologia*. 2015, 79:138-46
- Holtbernd F, Deppe M, Bachmann R, Mohammadi S, Ringelstein EB, **Reilmann R**. Deficits in tongue motor control are linked to microstructural brain damage in multiple sclerosis: a pilot study. *BMC Neurol*. 2015 Oct 8;15:190
- Reilmann R**, Lippross V, Hölzner E, Gigengack F, Bohlen S, Kugel H, Deppe M, Osada N, Lücke M, Riess O, Nguyen HP, Von Hörsten S, Schäfers K, Schäfers M, Jacobs AH, Hermann S. FDG  $\mu$ PET Fails

- to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study. *J Huntingtons Dis.* 2015, 4:37-47
10. Maetzler W, Ellerbrock M, Heger T, Sass C, Berg D, **Reilmann R**. Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study. *PLoS One.* 2015 Apr 22;10(4):e0123914
  11. Schaeffer E, Maetzler W, Liepelt-Scarfone I, Sass C, **Reilmann R**, Berg D. Quantitative motor assessment of dyskinesias in Parkinson's disease. *J Neural Transm.* 2015, 122:1271-8
  12. Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Santos RD, Coleman AJ, Carter K, Creighton S, Bechtel N, Bohlen S, **Reilmann R**, Johnson HJ, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. *Mov Disord.* 2015, 30:393-401
  13. **Reilmann R**, Rouzade-Dominguez ML, Saft C, Süßmuth SD, Priller J, Rosser A, Rickards H, Schöls L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B. A Randomized, Placebo-Controlled Trial of AFQ056 for the Treatment of Chorea in Huntington's Disease. *Mov Disord.* 2015, 30:427-31
  14. Sampaio C, Borowsky B, **Reilmann R**. Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. *Mov Disord.* 2014, 29:1419-28.
  15. **Reilmann R**, Leavitt BR, Ross CA. Huntington's disease: a field on the move. Introduction. *Mov Disord.* 2014, 29:1333-4
  16. **Reilmann R**, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. *Mov Disord.* 2014, 29:1335-41
  17. Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, **Reilmann R**, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nat Rev Neurol.* 2014, 10:204-16
  18. Bank PJ, van Rooijen DE, Marinus J, **Reilmann R**, van Hilten JJ. Force modulation deficits in complex regional pain syndrome: A potential role for impaired sense of force production. *Eur J Pain.* 2014 Jan 2. doi: 10.1002/j.1532-2149.2013.00446.x. [Epub ahead of print] PubMed PMID: 24382670
  19. **Reilmann R**. The pridopidine paradox in Huntington's disease [Editorial]. *Mov Disord* 2013, 28:1321-4
  20. **Reilmann R**. Pharmacological treatment of chorea in Huntington's disease: good clinical practice versus evidence based guideline. *Mov Disord* 2013, 28:1030-3
  21. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, **Reilmann R**, Stout JC, Langbehn DR; the TRACK-HD Investigators. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *Lancet Neurol.* 2013, 12:637-49
  22. Hart EP, Marinus J, Burgunder JM, Bentivoglio AR, Craufurd D, **Reilmann R**, Saft C, Roos RA; the REGISTRY Investigators of the European Huntington's Disease Network. Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease. *Mov Disord* 2013, 28:1142-5
  23. Squitieri F, Landwehrmeyer B, **Reilmann R**, Rosser A, Garcia de Yébenes J, Prang A, Ivkovic J, Bright J, Rembratt A. One-year safety and tolerability profile of pridopidine in patients with Huntington disease. *Neurology* 2013, 80:1086-94.
  24. **Reilmann R**, Holtbernd F, Bachmann R, Mohammadi S, Ringelstein EB, Deppe M. Grasping multiple sclerosis: do quantitative motor assessments provide a link between structure and function? *J Neurol* 2013, 2:407-14
  25. Bohlen S, Ekwall C, Hellström K, Vesterlin H, Björnefur M, Wiklund L, **Reilmann R**. Physical therapy in Huntington's disease - toward objective assessments? *Eur J Neurol* 2013, 202:389-93
  26. van den Bogaard SJ, Dumas EM, Hart EP, Milles J, **Reilmann R**, Stout JC, Craufurd D, Gibbard CR, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA. Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up. *AJNR Am J Neuroradiol.* 2013, 34:317-22
  27. Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SM, Hyare H, Langbehn DR, Jones R, Leavitt BR, Roos RA, Durr A, Johnson H, Lehericy S, Craufurd D, Kennard C, Hicks SL, Stout JC, **Reilmann R**, Tabrizi SJ; the TRACK-HD investigators. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. *Hum Brain Mapp* 2013, 34:519-29
  28. **Reilmann R**. Huntington's disease: towards disease modification – gaps and bridges, facts and opinions. *Basal Ganglia* 2012, 2:241-248
  29. **Reilmann R**. An important step towards translation of stem cell therapies in clinical applications for neurodegenerative diseases and beyond? *Mov Disord* 2012, 27:1355-6
  30. Delmaire C, Dumas EM, Sharman MA, van den Bogaard SJ, Valabregue R, Jauffret C, Justo D, **Reilmann R**, Stout JC, Craufurd D, Tabrizi SJ, Roos RA, Durr A, Lehericy S. The structural correlates of functional deficits in early Huntington's disease. *Hum Brain Mapp* 2012, Mar 22 doi: 10.1002/hbm.22055 [Epub ahead of print] PubMed PMID: 22438242.
  31. van den Bogaard SJ, Dumas EM, Milles J, **Reilmann R**, Stout JC, Craufurd D, van Buchem MA, van der Grond J, Roos RA. Magnetization transfer imaging in premanifest and manifest Huntington disease. *Am J Neuroradiol* 2012, 33:884-9
  32. **Reilmann R**, Rumpf S, Beckmann H, Koch R, Ringelstein EB, Lange HW. Huntington's disease: Objective assessment of posture – a link between motor and functional deficits. *Mov. Disord* 2012, 27:555-9
  33. **Reilmann R**. Does chromatin modulation provide the first wet-biomarker for Huntington's disease? *Mov. Disord* 2012, 27:473
  34. Tabrizi SJ, **Reilmann R**, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR; the

- TRACK-HD investigators. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. *Lancet Neurol* 2012, 11:42-53
35. Dumas E, van den Bogaard SJA, Ruber ME, **Reilmann R**, Stout JC, Craufurd D, Hicks SL, Kennard C, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RAC. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. *Hum Brain Mapp* 2012, 33:203-12
  36. **Reilmann R**, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington's disease - toward objective and quantitative measures. *Mov Disord* 2011, 26:2267-73
  37. de Yébenes JG, Landwehrmeyer B, Squitieri F, **Reilmann R**, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J; for the MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2011, 10:1049-1057
  38. **Reilmann R**. Progression of premanifest and early Huntington's disease detectable after 1 year—does TRACK-HD open the door to disease-modifying trials in HD and beyond? *Mov Disord* 2011, 26:605
  39. Vaccarino AL, Sills T, Anderson KE, Biglan K, Borowsky B, Giuliano J, Guttman M, Ho AK, Kennard C, Kupchak P, Landwehrmeyer GB, Michell A, Paulsen JS, **Reilmann R**, van Kammen DP, Warner JH, Evans K. Assessment of motor symptoms and functional impact in prodromal and early Huntington Disease. *PLoS Curr* 2011, Jun 14;2:RRN1244
  40. López-Sendón JL, Royuela A, Trigo P, Orth M, Lange H, **Reilmann R**, Keylock J, Rickards H, Piacentini S, Squitieri F, Landwehrmeyer B, Witjes-Ane MN, Jurgens, CK, Roos RA, Abaira V, de Yébenes JG; and the European HD Network. What is the impact of education on Huntington's disease? *Mov Disord* 2011, 26:1489-95
  41. Sitek E, Soltan W, Wiczorek D, Schinwelski M, Robowski P, **Reilmann R**, Guzinska K, Krysa W, Slawek J. Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia. *J Int Neuropsychol Soc* 2011, 17:788-95
  42. Kandasamy M, **Reilmann R**, Winkler J, Bogdahn U, Aigner L. Transforming growth factor-beta signaling in the neural stem cell niche: a therapeutic target for Huntington's disease. *Neurol Res Int* 2011, :124256
  43. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, **Reilmann R**, Stout JC; TRACK-HD Investigators. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. *Lancet Neurol* 2011, 10:31-42
  44. **Reilmann R**, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, Auer DP, Ringelstein EB, Lange HW. Grasping premanifest Huntington's disease - shaping new endpoints for new trials. *Mov Disord* 2010, 25:2858-62
  45. Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ, Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA, Landwehrmeyer GB, Langbehn DR, Stout JC, Tabrizi SJ, **Reilmann R**. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. *Neurology* 2010, 75:2150-60
  46. Sturrock A, Laule C, Decolongon J, Dar Santos R, Coleman AJ, Creighton S, Bechtel N, **Reilmann R**, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. *Neurology* 2010, 75:1702-10
  47. **Reilmann R**, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, Auer DP, Ringelstein EB, Lange HW. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. *Mov Disord* 2010, 25:2195-202
  48. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RAC, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, **Reilmann R**, Landwehrmeyer GB, Stout GC and the TRACK-HD Investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *Lancet Neurol* 2009, 8:791-801
  49. Horváth R, **Reilmann R**, Holinski-Feder E, Ringelstein EB, Klopstock T. The role of complex I genes in MELAS: a novel heteroplasmic mutation 3380G>A in ND1 of mtDNA. *Neuromusc Disord* 2008, 18:553-556
  50. Bachmann R, **Reilmann R**, Schwindt W, Kugel H, Heindel W, Kramer S. FLAIR imaging for multiple sclerosis: a comparative MR study at 1.5 and 3.0 Tesla. *Eur Radiol* 2006 16:915-21
  51. **Reilmann R**, Imai T, Ringelstein EB, Gaubitz M, Niederstadt TU, Paulus W, Husstedt IW. Remission of progressive multifocal leucoencephalopathy in SLE after treatment with cidofovir: a 4 year follow up. *J Neurol Neurosurg Psych* 2005, 76:1304-5
  52. Bender A, Auer DP, Merl T, **Reilmann R**, Saemann P, Yassouridis A, Weindl A, Dose M, Bender J, Gasser T, Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington's Disease. *J Neurol* 2005, 252:36-41
  53. Konrad C, Vollmer-Haase J, Gaubitz M, Nabavi DG, **Reilmann R**, Knecht S. Fracture of the odontoid process complicating tardive dystonia. *Mov Disord* 2004, 19:983-985
  54. Muratori L, **Reilmann R**, Gordon AM. Coordination of fingertip forces during precision grasping in multiple system atrophy. *Neuropsychologia* 2003, 41:1498-508
  55. Floel A, **Reilmann R**, Frese A, Ludemann P. Anticonvulsants for Creutzfeldt-Jakob disease? *Lancet* 2003, 361: 224
  56. Salimi I, Frazier W, **Reilmann R**, Gordon AM. Selective use of visual information signaling objects' center of mass for anticipatory control of manipulative fingertip forces. *Exp Brain Res* 2003, 150:9-18
  57. **Reilmann R**, Gordon AM, Henningsen H. Initiation and development of fingertip forces during whole-hand grasping. *Exp Brain Res* 2001; 140:443-452

58. **Reilmann R**, Kirsten F, Quinn L, Marder K, Henningsen H, Gordon AM. Objective assessment of progression of Huntington's Disease – a three year follow-up study. *Neurology* 2001, 57:920-924
59. Quinn L, **Reilmann R**, Marder K, Gordon AM. Altered movement trajectories and force control during object transport in Huntington's Disease. *Mov Disord* 2001, 16:469-480
60. Gordon AM, Quinn L, **Reilmann R**, Marder K. Coordination of precision grip in Huntington's Disease. *Exp Neurol* 2000, 163:136-148
61. Gordon AM, **Reilmann R**. Getting a grasp on research: Does treatment taint testing of Parkinsonian patients? *Brain* 1999, 122:1597-1598
62. **Reilmann R**, Rolf LH, Lange HW. Huntington's disease: N-methyl-D aspartate receptor co-agonist glycine is increased in platelets. *Exp Neurol* 1997, 144:416-419
63. **Reilmann R**, Rolf LH, Lange HW. Decreased alanine and isoleucine in plasma of patients with Huntington's disease. *Acta Neurol Scand* 1995, 91:222-224
64. **Reilmann R**, Rolf LH, Lange HW. Huntington's disease: the neuroexcitotoxin aspartate is increased in platelets and decreased in plasma. *J Neurol Sci* 1994, 127:48-53

## COLLABORATIVE RESEARCH

(peer reviewed)

1. Minkova L, Eickhoff SB, Abdulkadir A, Kaller CP, Peter J, Scheller E, Lahr J, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S; TRACK-HD Investigators. Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance. *Hum Brain Mapp*. 2016, 37:67-80
2. Minkova L, Scheller E, Peter J, Abdulkadir A, Kaller CP, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S; TrackOn-HD Investigators. Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. *Front Hum Neurosci*. 2015, 9:634
3. McColgan P, Seunarine KK, Razi A, Cole JH, Gregory S, Durr A, Roos RA, Stout JC, Landwehrmeyer B, Scahill RI, Clark CA, Rees G, Tabrizi SJ; Track-HD Investigators. Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease. *Brain*. 2015, 138:3327-44
4. Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2015, 14:39-47
5. Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network. Suicidal ideation in a European Huntington's disease population. *J Affect Disord*. 2013, 151:248-58
6. HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. *JAMA Neurol*. 2013, 70:25-33
7. Brossman B, Williams JK, Downing N, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Development of the Huntington disease work function scale. *J Occup Environ Med*. 2012, 54:1300-8
8. Smith MM, Mills JA, Epping EA, Westervelt HJ, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. *Neuropsychology*. 2012, 26:664-9
9. Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. *J Neurol Neurosurg Psychiatry*. 2012, 83:612-9
10. Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. 8OHdG as a marker for Huntington disease progression. *Neurobiol Dis*. 2012, 46:625-34
11. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. *Neurology*. 2012; 78:690-5
12. Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network, Arning L. NMDA receptor gene variations as modifiers in Huntington disease: a replication study. *PLoS Curr*. 2011, 4:3:RRN1247. doi: 10.1371/currents.RRN1247. PubMed PMID: 21989477
13. Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington's Disease Network. Discrepancies in reporting the CAG repeat lengths for Huntington's disease. *Eur J Hum Genet*. 2012, 20:20-6
14. Carlozzi NE, Stout JC, Mills JA, Duff K, Beglinger LJ, Aylward EH, Whitlock KB, Solomon AC, Queller S, Langbehn DR, Johnson SA, Paulsen JS; Predict-Hd Investigators Of The Huntington Study Group.



- Estimating premorbid IQ in the prodromal phase of a neurodegenerative disease. *Clin Neuropsychol.* 2011, 25:757-77
15. Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. *J Neurol Neurosurg Psychiatry* 2011, 82:1409-12
  16. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB; Investigators of the European Huntington's Disease Network. Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. Version 2. *PLoS Curr.* 2010 Sep 28 [revised 2011 Apr 13];2:RRN1184. PubMed PMID: 20890398; PubMed Central PMCID: PMC2947793.
  17. Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS; PREDICT-HD Investigators Coordinators of Huntington Study Group (HSG). Cerebral cortex structure in prodromal Huntington disease. *Neurobiol Dis.* 2010, 40:544-54
  18. Aziz NA, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. *Neurology.* 2009, 73:1280-5

### BOOK CHAPTERS

1. **Reilmann R**, Schubert R, Chapter: Motor outcome measures in HD clinical trials. Aminoff MJ, Boller F, Swaab DF (eds) *Hand book of Clinical Neurology*, 3rd Series, Feigin A, Anderson K (eds) *Huntington's Disease*, Elsevier (in press)
2. **Reilmann R**, Knecht S, Henningsen H. Chapter 23: Spinale Tumoren. In: Berlit P (ed) *Clinical Neurology*, 3rd edition, Springer Verlag, Berlin, 2011, ISBN 978-3-642-16919-9, pp. 559-578
3. **Reilmann R**. Chapter 26: Grip force analysis in Huntington's Disease – a biomarker for clinical trials? In: Nowak, D, Hermsdörfer J (eds): *Sensorymotor control of grasping*, Cambridge University Press, Cambridge, 2009, ISBN 978-0-521-88157-9, pp. 326-332
4. **Reilmann R**, Henningsen H. Chapter 23: Spinal Tumors. In: Berlit P (ed) *Clinical Neurology*, 2nd edition, Springer Verlag, Berlin, 2006, ISBN 3-540-01982-0, pp. 510-528
5. **Reilmann R**. Motor deficits as biomarkers in Huntington's disease: perspectives for neuroacanthocytosis syndromes. In: Danek A (ed) *Neuroacanthocytosis Syndromes*, Springer Verlag, Berlin, 2004, ISBN 1-420-2897-0, pp. 233-242
6. **Reilmann R**, Henningsen H. Kapitel 23: Spinale Tumoren. In: Berlit P (ed) *Klinische Neurologie*, Springer Verlag, Berlin, 1999, ISBN 3-540-65281-7, pp. 508-528

### REVIEWER FOR JOURNALS, GRANTS AND INSTITUTIONS

**Journals (selection):** *Movement Disorders Journal*, *Journal Huntington's Disease*, *Neurology*, *Brain*, *Journal of Neurology Neurosurgery and Psychiatry*, *Cerebral Cortex*, *Human Brain Mapping*, *Neuroradiology*, *PLoS ONE*, *PLoS Currents Huntington's Disease*, *Clinical Neurophysiology*, *Stroke*, *Experimental Brain Research*, *BMC Neurology*, *Biological Psychiatry*

**Grants & Institutions (selection):** *European Huntington's Disease Network* / *National Institute for Health Research – NHS*, *Great Britain* / *National Science Foundation – NSF*, *United States* / *Gossweiler Foundation*, *Switzerland* / *Humboldt Foundation*, *Germany* / *Medical Research Council (MRC)*, *Great Britain*

### INVITED SPEAKER

(selection)

- 2016 Reilmann, R: "Digital Health Technology in Movement Disorders", TEVA Symposium on Emerging Technologies and Therapies in Movement Disorders, International Congress of Parkinson's Disease and Movement Disorders, Berlin, Germany
- 2016 Reilmann, R: "Huntington' disease – from clinical features to assessment tools", TEVA Clinical Research Symposium, International Congress of Parkinson's Disease and Movement Disorders, Berlin, Germany
- 2016 Reilmann, R: "Huntington' disease – on the path to treatments?", *Neurology Colloquium*, Dept. of Molecular Neurology, Friedrich-Alexander-University, Erlangen-Nuernberg, Germany
- 2016 Reilmann, R: "DBS in Huntington' disease – Contra", International Conference on Deep Brain Stimulation, Düsseldorf, Germany
- 2016 Reilmann, R: "Update Huntington's disease", *Regionaler Qualitätszirkel*, Detmold, Germany
- 2015 Reilmann, R: "Update Huntington's Disease", 7<sup>th</sup> TEVA Local CNS Symposium, Hamburg, Germany
- 2015 Reilmann, R: "Phenotyping tgHD Minipigs – from behaviour to imaging". *Large Animal Models in Neurodegeneration Workshop*, Chateau Liblice, Czech Republic
- 2015 Reilmann, R: „Q-Motor Overview“, *Huntington Study Group Meeting*, Tampa, FL, USA

- 2015 Reilmann, R: „Q-Motor and Q-Cog – novel developments for endpoints in clinical trials in Huntington’s disease targeting stem cell delivery“. REPAIR-HD EU Framework Program Consortium Meeting, Edinburgh, Scotland, Great Britain
- 2015 Reilmann, R: “Repeat Diseases in Neurology – Huntington’s Disease” Deutsche Gesellschaft für Neurologie (DGN) 2015, Düsseldorf, Germany
- 2015 Reilmann, R: “Huntington’sche Krankheit: Laufende Klinische Studien und neue Endpunkte ” Deutsche Gesellschaft für Neurologie (DGN) 2015, Düsseldorf, Germany
- 2015 Reilmann, R: „Huntington’s Disease as a model for translational neurobiology – from the gene to the clinic“. Moving Beyond / PhenoRat EU Framework Workshop Week, Crete, Greece
- 2015 Reilmann, R: „Q-Motor – translation of a novel endpoint into clinical application“. Moving Beyond / PhenoRat EU Framework Workshop Week, Crete, Greece
- 2015 Reilmann, R: “Biomarkers of premanifest and manifest Huntington’s disease – ready for clinical trails?”, 19th International Congress of Parkinson’s Disease and Movement Disorders, San Diego, USA
- 2014 Reilmann, R: “Update Huntington’s Disease”, TEVA Local CNS Symposium, Düsseldorf, Germany
- 2014 Reilmann, R: “Q-Motor endpoints for clinical trials in HD”, Huntington Study Group Meeting, Minneapolis, MN, USA
- 2014 Reilmann, R: “Novel diagnostic criteria for HD”, Huntington Study Group Meeting, Minneapolis, MN, USA
- 2014 Reilmann, R: “Safety and Tolerability of Selisistat for the Treatment of Huntington’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial”, Annual Meeting of the American Academy of Neurology (AAN), Philadelphia, USA
- 2014 Reilmann, R: “Q-Motor Biomarker in Huntington’s disease ”, Wissenschaftliches Symposium anlässlich des 20 jährigen Bestehens des Huntington-Zentrums NRW, Bochum, Germany
- 2014 Reilmann, R: “Q-Motor in Huntington’s disease – the DBS project”, Meeting des BMBF Projektes Tiefenhirnstimulation in HD, Düsseldorf, Germany
- 2014 Reilmann, R: “Huntington’s disease – an Update”, Deutsche Gesellschaft für klinische Neurophysiologie (DGKN), Berlin, Germany
- 2014 Reilmann, R: “Huntington’s disease: gaps & bridges – facts & opinions”, Neurologische Universitätsklinik, Eberhard Karls Universität Tübingen, Tübingen, Germany
- 2013 Reilmann, R: “Q-Motor and other motor assessments in HD”, Huntington Study Group Meeting, Charlotte, North Carolina, USA
- 2013 Reilmann, R: “TRACK-tgHD-Minipig – a multimodal phenotyping study”. Large Animal Models in Neurodegeneration Workshop, Chateau Liblice, Czech Republic
- 2013 Reilmann, R: “Diagnosis of HD and the premotor stages”, The Movement Disorders Society Workshop on Design, Conduct and Interpretation of Clinical Trials in Movement Disorders, Toulouse, France
- 2013 Reilmann, R: “Clinical progression of HD and relevant clinical outcomes”, The Movement Disorders Society Workshop on Design, Conduct and Interpretation of Clinical Trials in Movement Disorders, Toulouse, France
- 2013 Reilmann, R: “Overview on outcome measures in HD and PD”, The Movement Disorders Society Workshop on Design, Conduct and Interpretation of Clinical Trials in Movement Disorders, Toulouse, France
- 2013 Reilmann, R: „Huntington’s disease – from clinic to the bench and backwards“. MovingBeyond/PhenoRat EU Framework Training Week, Nijmegen, The Netherlands
- 2013 Reilmann, R: “Premanifest Huntington’s disease – motor assessments reviewed”, Plenary talk, World Congress of Huntington’s Disease, Rio de Janeiro, Brazil
- 2013 Reilmann, R: “Die Huntington’sche Krankheit – brauchen wir Glück oder Schwein, um erfolgreich zu sein?” Institut für Humangenetik, University of Muenster, Muenster, Germany
- 2013 Reilmann, R: “Biomarkers of prodromal Huntington’s disease”, 17th International Congress of Parkinson’s Disease and Movement Disorders, Sydney, Australia
- 2013 Reilmann, R: “Differentialdiagnostik und (neue) Therapiestrategien der Chorea Huntington”, 2. Forum für Bewegungsstörungen, Martha-Maria Halle-Dölau, Germany
- 2013 Reilmann, R: „Translationale Untersuchung des M. Huntington im Schweinmodell“, ISMRM Doktoranden-Seminar Deutschland, Muenster, Germany
- 2013 Reilmann, R: “Treatment of the movement disorders in Huntington’s disease”, Second International Expert Meeting on Hyperkinetic Movement Disorders, Malta
- 2013 Reilmann, R: “Q-Motor - quantitative motor endpoints for clinical trials in Huntington’s disease ”, National Institute of Neurological Disorders and Stroke (NINDS), Workshop on Biomarkers for Huntington’s disease, Washington, DC, USA
- 2012 Reilmann, R: “Motor symptoms in Huntington’s disease - diagnosis, quantification and treatments”, Huntington’s disease in Clinical Practice Symposium, Huntington Study Group Meeting, Seattle, USA
- 2012 Reilmann, R: “Huntington’s disease - neurology”, Chorea, ataxia and other dyskinesias symposium, Olomouc, Czech Republic
- 2012 Reilmann, R: “Assessment of motor symptoms in Huntington’s disease in clinical trials”, European Huntington’s Disease Network Meeting, Stockholm
- 2012 Reilmann, R: “Novel biomarkers and clinical perspectives in Huntington’s disease”, Symposium on Hyperkinetic Movement Disorders, Dubrovnik, Croatia
- 2012 Reilmann, R: “Huntington’s disease: How are we defining disease progression? What are the most promising targets for disease modification?”, Knowledge gaps in Parkinson’s disease and other movement disorders, Genova, Italy

- 2011 Reilmann, R: "Q-Motor in Huntington's disease", Plenary talk, World Congress of Huntington's Disease, Melbourne, Australia
- 2011 Reilmann, R: "Huntington's disease – from TRACK-HD to Minipigs". Large Animal Models in Neurodegeneration Workshop, Chateau Liblice, Czech Republic
- 2011 Reilmann, R: "Motor phenotype of choreatic diseases – a video based seminar", Movement Disorders Society Meeting, Toronto, Canada
- 2011 Reilmann, R: "Q-Motor – novel outcome measures for clinical trials in Movement Disorders", Seminar Invitation, Rush University, Chicago, USA
- 2011 Reilmann, R: "Update Huntington's Disease – from bench to bed", Deutsche Gesellschaft für klinische Neurophysiologie (DGKN), Muenster, Germany
- 2011 Reilmann, R: "Q-Motor – quantitative motor assessments in Movement Disorders", Deutsche Gesellschaft für klinische Neurophysiologie (DGKN), Muenster, Germany
- 2010 Reilmann, R: "TRACK-HD: Quantitative motor assessments track progression of Huntington's Disease", Plenary talk, European Huntington's Disease Network Meeting, Prague, Czech Republic
- 2010 Reilmann, R: "Neuroprotective Therapies for Huntington's Disease – what do we know and what is under development", Plenary talk, Movement Disorders Society Meeting, Buenos Aires, Argentina
- 2010 Reilmann, R: "The motor phenotype of Huntington's Disease – video based samples", Deutsche Gesellschaft für klinische Neurophysiologie (DGKN), Halle, Germany
- 2010 Reilmann, R: "Quantitative motor assessments in PREDICT-HD", PREDICT-HD investigators Meeting, San Francisco, USA
- 2009 Reilmann, R: "Quantitative motor assessments in AFQ056", AFQ056 investigators Meeting, Berlin, Germany
- 2009 Reilmann, R: "Functional Biomarkers of Huntington's Disease - the message from TRACK-HD", World Congress of Huntington's Disease, Vancouver, Canada
- 2009 Reilmann, R: "Motor Phenotype assessment in Huntington's Disease - rating scales and TRACK-HD", CHDI Workshop on Presymptomatic Rating Scales, Toronto, Canada
- 2009 Reilmann, R: "Quantitative motor assessment in Huntington's Disease - first results from the Multi-Center Study TRACK-HD suggest new functional biomarkers for clinical trials", TRACK-HD Meeting, Paris, France
- 2008 Reilmann, R: "The motor Phenotype of Huntington's disease - including video samples ", Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Berlin, Germany
- 2008 Reilmann, R: "The UHDRS Teaching Video – review of motor symptoms and introduction of the new online motor certification system", Huntington Study Group Meeting (HSG), Tampa, Florida, USA
- 2008 Reilmann, R: "Motor Assessment in Huntington's Disease – new strategies and perspectives", European Huntington's Disease Network Meeting (EHDN), Lisbon, Portugal
- 2008 Reilmann, R: "Motor Rater Training for the UHDRS – video based review of clinical samples", French HD Investigators Meeting, Paris, France
- 2008 Reilmann, R: "Quantitative motor assessments in the development of biomarkers in Huntington's Disease", Biomarker Working Group Meeting, European Huntington's Disease Network (EHDN), London, Great Britain
- 2007 Reilmann, R: "New Motor Rater Trainings using the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score", Huntington Study Group Meeting (HSG), Boston, MA, USA
- 2007 Reilmann, R: "Small animal PET and MRI in rats and mice transgenic for Huntington's Disease", Deutsche Gesellschaft für Neurologie (DGN), Berlin, Germany
- 2007 Reilmann, R: "Motor assessment in Huntington's Disease: new methods, new devices, new readouts", European Huntington's Disease Network Meeting (EHDN), Dresden, Germany
- 2007 Reilmann, R: "Video assessment of UHDRS examinations in patients with Huntington's Disease", Motor Workgroup Meeting, European Huntington's Disease Network (EHDN), Leiden, The Netherlands
- 2006 Reilmann, R: "Grip-force variability in asymptomatic carriers of the Huntington gene - a biomarker for presymptomatic clinical studies?", Deutsche Gesellschaft für Neurologie (DGN), Mannheim, Germany
- 2006 Reilmann, R: "Motor assessment in Huntington's disease – new rater training – new readouts", European Huntington's Disease Network Meeting (EHDN), Blankenberge, Belgium
- 2006 Reilmann, R: "Small animal PET and MRI imaging in rats transgenic for Huntington's Disease", Imaging and Biomarker Workgroup Meeting, European Huntington's Disease Network (EHDN), Lund, Sweden
- 2006 Reilmann, R: "Motor biomarkers of Huntington's Disease", Motor Workgroup Meeting, European Huntington's Disease Network (EHDN), Muenster, Germany
- 2006 Reilmann, R: "Objective assessment of chorea in Huntington's Disease", Motor Workgroup Meeting, European Huntington's Disease Network (EHDN), Muenster, Germany
- 2005 Reilmann, R: "Grip-force variability in asymptomatic carriers of the Huntington gene - a biomarker for presymptomatic clinical studies?" Deutsche Gesellschaft für Neurologie (DGN) 2005, Wiesbaden, Germany
- 2004 Reilmann R: "Objective neurophysiological assessment of motor deficits in Huntington's Disease – a search for biomarkers" European Huntington's Disease Network Meeting (EHDN). Madrid, Spain
- 2002 Reilmann R: "Neurophysiological assessment of motor deficits in Huntington's Disease – a new approach for biomarkers in clinical studies." Biannual Conference of the Hereditary Disease Foundation (HDF), "Changes, Advances and good news in CAG-Repeat Disorders", Cambridge, MA, USA
- 2002 Reilmann R: "Objective assessment of progression in Huntington's Disease – a three year follow-up study." Frontiers in Neurodegeneration Workshop on Huntington's Disease, Reischensberg, Germany

- 2001 Reilmann R: "The coordination of multifingered grasping and individuation of isometric force development."  
Motor Control Workshop, Columbia University, New York, USA

### **CHAIR / HOST OF CONFERENCES / WORKSHOPS / SYMPOSIA**

(selection)

- 2016 Co-Chair Meeting of Task Force on the Redefinition of diagnostic criteria for Huntington's disease, International Congress of Parkinson's Disease and Movement Disorders, Berlin, Germany
- 2015 Session Chair: "Repeat Diseases in Neurology" Deutsche Gesellschaft für Neurologie (DGN) 2015, Düsseldorf, Germany
- 2015 Session Chair: Highlights in Huntington's disease, Huntington Study Group Meeting, Orlando, FL, USA
- 2015 Session Chair: The role of large animal models in translation – the future. Large Animal Models in Neurodegeneration Workshop, Chateau Liblice, Czech Republic
- 2015 Co-Chair Meeting of Task Force on the Redefinition of diagnostic criteria for Huntington's disease, International Congress of Parkinson's Disease and Movement Disorders, San Diego, CA, USA
- 2014 Session Chair: Highlights in Huntington's disease, Huntington Study Group Meeting, Minneapolis, MI, USA
- 2014 REPAIR-HD EU-FP7 Project Workshop, George-Huntington-Institute, Münster, Germany
- 2013 Co-Chair: Large Animal Models in Neurodegeneration Workshop & CHDI Large Animal Working Group Meeting, Chateau Liblice, Czech Republic
- 2013 Host & Chair: Neuroprotective Working Group Meeting, European Huntington's Disease Network, Lisboa, Portugal
- 2011 Session Chair: Chorea - clinical presentations, Movement Disorders Society Meeting, Toronto, Canada
- 2011 Session Chair: Novel assessments in Movement Disorders, Germany Society for Neurophysiology Annual Meeting, Muenster, Germany
- 2011 Host & Chair: Large Animals in Neurodegeneration Workshop, Liblice Castle, Prague, Czech Republic
- 2010 Host & Chair: Neuroprotective Working Group Meeting, European Huntington's Disease Network, Prague, Czech Republic
- 2010 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Prague, Czech Republic
- 2009 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Leiden, Netherlands
- 2009 Host & Chair: Neuroprotective Working Group Meeting, European Huntington's Disease Network, Lisbon, Portugal
- 2008 Host & Chair: Neuroprotective Working Group Meeting, European Huntington's Disease Network, Lisbon, Portugal
- 2008 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Bern, Switzerland
- 2007 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Dresden, Germany
- 2007 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Leiden, Netherlands
- 2006 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Blankenberge, Belgium
- 2006 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Muenster, Germany
- 2005 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Manchester, England
- 2004 Host & Chair: Motor Working Group Meeting, European Huntington's Disease Network, Madrid, Spain

Muenster, June 2016



Dr. Ralf Reilmann